Shares of VistaGen Therapeutics Inc VTGN rocketed up over 40 percent to $1.36 in after-hours trading on Thursday — a mere fraction of the 500 percent upside implied by a late-day note from Oppenheimer.
The Analyst
Oppenheimer’s Jay Olson initiated coverage on VistaGen with an Outperform rating and $6 price target.
2 Catalysts Ahead
Olson’s rating hinges on positive Phase 2 trial results for VistaGen’s rapid acting oral antidepressant, AV-101.
Results from the first trial, with 25 participants, are expected by the end of the year. The second trial is much larger with 180 subjects. Those results aren't expected to be released until mid-2019.
If the Phase 2 trials are successful, Olson sees VistaGen beginning pivotal trials by early-2020, with potential NDA filing in 2022. The antidepressant would then be expected to launch in 2023.
“Our view [is that] the company is underappreciated and undervalued, with a novel, potentially best-in-class, rapid acting oral antidepressant,” said Olson in a note.
Related Links:
SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.